Comparison of inflammatory markers for the prediction of atrial fibrillation recurrence following cryoablation.

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2024-09-12 DOI:10.1080/17520363.2024.2395236

Koray Kalenderoglu,Mert Ilker Hayiroglu,Tufan Cinar,Melih Oz,Gokcem Ayan Bayraktar,Ridvan Cam,Kadir Gurkan

引用次数: 0

Abstract

Aim: The aim of this study is to investigate the value of inflammatory markers for atrial fibrillation (AF) recurrence prediction after cryo-balloon ablation (CA).Materials & methods: The study included 399 patients divided into two groups by AF recurrence after CA. Inflammatory markers including uric acid/albumin ratio (UAR), systemic immune inflammation index (SIII) and CRP/albumin ratio (CAR) were evaluated.Results: UAR, SIII, and CAR were independently associated with the risk of recurrence in AF patients following CA. In ROC curve analysis, CAR had a greater area under curve (AUC:0.73) value than either SIII (AUC:0.68) or UAR (AUC:0.64).Conclusion: Our study results indicate that CAR compared with SIII and UAR had a greater predictive value than others inflammatory markers in predicting AF recurrence post-CA.

查看原文本刊更多论文

冷冻消融术后预测心房颤动复发的炎症标志物比较。

目的：本研究旨在探讨炎症标志物对低温球囊消融术（CA）后心房颤动（AF）复发的预测价值：研究纳入了 399 名患者，按 CA 后房颤复发情况分为两组。研究评估了包括尿酸/白蛋白比值（UAR）、全身免疫炎症指数（SIII）和 CRP/白蛋白比值（CAR）在内的炎症指标：结果：尿酸/白蛋白比值、全身免疫炎症指数（SIII）和CRP/白蛋白比值（CAR）与房颤患者CA术后的复发风险独立相关。在 ROC 曲线分析中，CAR 的曲线下面积（AUC:0.73）值高于 SIII（AUC:0.68）或 UAR（AUC:0.64）：我们的研究结果表明，与 SIII 和 UAR 相比，CAR 在预测心房颤动术后心房颤动复发方面具有更大的预测价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.